BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 22977237)

  • 1. Structure of the bone morphogenetic protein receptor ALK2 and implications for fibrodysplasia ossificans progressiva.
    Chaikuad A; Alfano I; Kerr G; Sanvitale CE; Boergermann JH; Triffitt JT; von Delft F; Knapp S; Knaus P; Bullock AN
    J Biol Chem; 2012 Oct; 287(44):36990-8. PubMed ID: 22977237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation.
    van Dinther M; Visser N; de Gorter DJ; Doorn J; Goumans MJ; de Boer J; ten Dijke P
    J Bone Miner Res; 2010 Jun; 25(6):1208-15. PubMed ID: 19929436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel mutation of ALK2, L196P, found in the most benign case of fibrodysplasia ossificans progressiva activates BMP-specific intracellular signaling equivalent to a typical mutation, R206H.
    Ohte S; Shin M; Sasanuma H; Yoneyama K; Akita M; Ikebuchi K; Jimi E; Maruki Y; Matsuoka M; Namba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Furuya H; Kamizono J; Kitoh H; Nakashima Y; Susami T; Haga N; Komori T; Katagiri T
    Biochem Biophys Res Commun; 2011 Apr; 407(1):213-8. PubMed ID: 21377447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A unique mutation of ALK2, G356D, found in a patient with fibrodysplasia ossificans progressiva is a moderately activated BMP type I receptor.
    Fukuda T; Kanomata K; Nojima J; Kokabu S; Akita M; Ikebuchi K; Jimi E; Komori T; Maruki Y; Matsuoka M; Miyazono K; Nakayama K; Nanba A; Tomoda H; Okazaki Y; Ohtake A; Oda H; Owan I; Yoda T; Haga N; Furuya H; Katagiri T
    Biochem Biophys Res Commun; 2008 Dec; 377(3):905-9. PubMed ID: 18952055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
    Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
    J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Constitutively activated ALK2 and increased SMAD1/5 cooperatively induce bone morphogenetic protein signaling in fibrodysplasia ossificans progressiva.
    Fukuda T; Kohda M; Kanomata K; Nojima J; Nakamura A; Kamizono J; Noguchi Y; Iwakiri K; Kondo T; Kurose J; Endo K; Awakura T; Fukushi J; Nakashima Y; Chiyonobu T; Kawara A; Nishida Y; Wada I; Akita M; Komori T; Nakayama K; Nanba A; Maruki Y; Yoda T; Tomoda H; Yu PB; Shore EM; Kaplan FS; Miyazono K; Matsuoka M; Ikebuchi K; Ohtake A; Oda H; Jimi E; Owan I; Okazaki Y; Katagiri T
    J Biol Chem; 2009 Mar; 284(11):7149-56. PubMed ID: 18684712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of FKBP12 and type II BMP receptors on signal transduction by ALK2 activating mutations associated with genetic disorders.
    Machiya A; Tsukamoto S; Ohte S; Kuratani M; Fujimoto M; Kumagai K; Osawa K; Suda N; Bullock AN; Katagiri T
    Bone; 2018 Jun; 111():101-108. PubMed ID: 29551750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
    Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
    J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
    Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
    Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro analyses of the dysregulated R206H ALK2 kinase-FKBP12 interaction associated with heterotopic ossification in FOP.
    Groppe JC; Wu J; Shore EM; Kaplan FS
    Cells Tissues Organs; 2011; 194(2-4):291-5. PubMed ID: 21525719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel bicyclic pyrazoles as potent ALK2 (R206H) inhibitors for the treatment of fibrodysplasia ossificans progressiva.
    Yamamoto H; Sakai N; Ohte S; Sato T; Sekimata K; Matsumoto T; Nakamura K; Watanabe H; Mishima-Tsumagari C; Tanaka A; Hashizume Y; Honma T; Katagiri T; Miyazono K; Tomoda H; Shirouzu M; Koyama H
    Bioorg Med Chem Lett; 2021 Apr; 38():127858. PubMed ID: 33609658
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutant activin-like kinase 2 in fibrodysplasia ossificans progressiva are activated via T203 by BMP type II receptors.
    Fujimoto M; Ohte S; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Suda N; Katagiri T
    Mol Endocrinol; 2015 Jan; 29(1):140-52. PubMed ID: 25354296
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Establishment of a novel model of chondrogenesis using murine embryonic stem cells carrying fibrodysplasia ossificans progressiva-associated mutant ALK2.
    Fujimoto M; Ohte S; Shin M; Yoneyama K; Osawa K; Miyamoto A; Tsukamoto S; Mizuta T; Kokabu S; Machiya A; Okuda A; Suda N; Katagiri T
    Biochem Biophys Res Commun; 2014 Dec; 455(3-4):347-52. PubMed ID: 25446088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1.
    Kaplan FS; Xu M; Seemann P; Connor JM; Glaser DL; Carroll L; Delai P; Fastnacht-Urban E; Forman SJ; Gillessen-Kaesbach G; Hoover-Fong J; Köster B; Pauli RM; Reardon W; Zaidi SA; Zasloff M; Morhart R; Mundlos S; Groppe J; Shore EM
    Hum Mutat; 2009 Mar; 30(3):379-90. PubMed ID: 19085907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The fibrodysplasia ossificans progressiva R206H ACVR1 mutation activates BMP-independent chondrogenesis and zebrafish embryo ventralization.
    Shen Q; Little SC; Xu M; Haupt J; Ast C; Katagiri T; Mundlos S; Seemann P; Kaplan FS; Mullins MC; Shore EM
    J Clin Invest; 2009 Nov; 119(11):3462-72. PubMed ID: 19855136
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
    Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
    Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fibrodysplasia ossificans progressiva-related activated activin-like kinase signaling enhances osteoclast formation during heterotopic ossification in muscle tissues.
    Yano M; Kawao N; Okumoto K; Tamura Y; Okada K; Kaji H
    J Biol Chem; 2014 Jun; 289(24):16966-77. PubMed ID: 24798338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hyperactive BMP signaling induced by ALK2(R206H) requires type II receptor function in a Drosophila model for classic fibrodysplasia ossificans progressiva.
    Le VQ; Wharton KA
    Dev Dyn; 2012 Jan; 241(1):200-14. PubMed ID: 22174087
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activation of G
    Ebner JK; König GM; Kostenis E; Siegert P; Aktories K; Orth JHC
    Bone; 2019 Oct; 127():592-601. PubMed ID: 31376533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2.
    Williams E; Bullock AN
    Bone; 2018 Apr; 109():251-258. PubMed ID: 28918311
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.